Key result
Thoracic radiotherapy for Hodgkin lymphoma is linked to ~2.3-fold higher odds of elevated coronary calcium.
Why the study?
Thoracic radiotherapy for Hodgkin lymphoma increases cardiovascular event risk, but the relation between coronary artery calcium score and cardiovascular events compared to non-cancer controls needed evaluation.
Does prior thoracic radiotherapy increase the prevalence of coronary artery calcium and cardiovascular events in Hodgkin lymphoma survivors compared to non-cancer controls?
Cross-Sectional (n=194)
No
Does prior thoracic radiotherapy increase the prevalence of coronary artery calcium and cardiovascular events in Hodgkin lymphoma survivors compared to non-cancer controls?
Hodgkin lymphoma survivors treated with thoracic radiotherapy have a significantly higher prevalence of coronary artery calcium and non-obstructive coronary artery disease, as well as an increased risk of long-term cardiovascular events, compared to a matched non-cancer control group.
Answers are grounded in this paper and cite their sources.
Indicates need for vigilant cardiovascular follow-up in Hodgkin lymphoma survivors after thoracic radiotherapy; leaves optimal screening strategy open.
Background: Thoracic radiotherapy is one of the corner stones of HL treatment, but it is associated with increased risk of cardiovascular events. As HL is often diagnosed at a young age, long-term follow-up including screening for coronary artery disease (CAD) is recommended. Objectives: This study aims to evaluate the presence of coronary artery calcium score (CACS) in relation to cardiovascular events in HL patients treated with thoracic radiotherapy compared to a non-cancer control group. Methods: Consecutive HL patients who underwent evaluation for asymptomatic CAD with coronary computed tomography angiography > 10 years after thoracic irradiation were included. The study population consisted of 97 HL patients matched to 97 non-cancer patients on gender, age, cardiovascular risk factors, and statin use. Results: Mean age during CT scan in the HL population was 45.5 ± 9.9 and in the non-cancer population 45.5 ± 10.3 years. CACS was elevated (defined as >0) in 49 (50.5%) HL patients and 30 (30.9%) control patients. HL survivors had an odds ratio of 2.28 [95% CI: 1.22–4.28] for having a CACS > 0 compared to the matched population (p = 0.006). Prevalence of CACS > 90th percentile differed significantly: 17.1% in HL survivors vs. 4.6% in the matched population (p = 0.009). Non-obstructive coronary artery stenosis was more prevalent in the HL population than in the control population (45.7% vs. 28.4%, respectively, p = 0.01). During follow-up of 8.5 [5.3; 9.9] years, nine HL patients experienced an event including two patients with a CACS of zero. No events occurred in the control population. Conclusion: In a matched study population, HL survivors have a higher prevalence of a CACS > 0 and an increased risk of cardiovascular events after thoracic irradiation compared to a matched non-cancer control group.
No takes yet. Share an insight, caveat, or question.
Polomski et al. (2023) conducted a cross-sectional in Hodgkin lymphoma survivors >10 years post-thoracic radiotherapy (n=194). Thoracic radiotherapy vs. Matched non-cancer controls (unexposed to thoracic radiotherapy) was evaluated on Elevated coronary artery calcium score (CACS > 0) (OR 2.28, 95% CI 1.22-4.28, p=0.006). Thoracic radiotherapy for Hodgkin lymphoma was associated with a higher prevalence of elevated coronary artery calcium and increased risk of cardiovascular events compared to matched non-cancer controls.
Synapse has enriched 10 related papers. Consider them for comparative context: